window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : April 17, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Biotech

  • Biotech,Cell & Gene Therapy,Clinical Development,Movers & Shakers,Pharmaceuticals and therapeutics,Rare Diseases

    Hans Schambye appointed as CEO of BOOST Pharma as BT‑101 advances toward Phase 3

    BOOST Pharma has appointed Hans Schambye as its new chief [...]

    February 11, 2026
  • Biotech,Drug Development,Oncology,Research & Development,Technology and platforms

    SPT Labtech and BellBrook Labs unveil high-throughput screening platform targeting VPS4B in cancer research

    SPT Labtech and BellBrook Labs have introduced a miniaturised high-throughput [...]

    February 11, 2026
  • Biotech,Global health,Immunology,Pharmaceuticals and therapeutics,Research & Development

    BNPP AM Alts invests $115M in ILiAD Biotechnologies to advance whooping cough vaccine

    BNP Paribas Asset Management Alts (BNPP AM Alts) has made [...]

    February 11, 2026
  • Biotech,Clinical Development,Clinical Trials,Oncology,Partnerships & Funding

    Evogene licenses microbiome cancer therapy BMC128 to Shanghai Lishan Biopharmaceuticals

    Evogene and Shanghai Lishan Biopharmaceuticals have entered into an exclusive [...]

    February 6, 2026
  • Biotech,Clinical Development,Clinical Trials,Infectious Diseases,Vaccines

    NeoVac reports Phase 1 and Phase 2 data for NeomiVac mRNA LNP covid-19 vaccine

    NeoVac has reported positive first-in-human Phase 1 and Phase 2 [...]

    February 6, 2026
  • Biotech,Clinical Development,European biotech,Immunology,Oncology,Partnerships & Funding,Research & Development

    Kahimmune Therapeutics signs exclusive licensing agreement with Gustave Roussy and SATT Paris-Saclay

    Kahimmune Therapeutics has signed an exclusive licensing agreement with Gustave [...]

    February 2, 2026
  • Biotech,Digital Health,Technology and platforms

    Research finds scientists view ELNs as ‘glorified filing cabinets’, driving duplication and shadow AI use

    A new survey by Sapio Sciences has found widespread frustration [...]

    January 30, 2026
  • Biotech,Cell & Gene Therapy,Drug Development,Healthcare leadership,Immunology

    TECregen appoints Dr Klaas Zuideveld as CEO to advance thymus regeneration platform

    TECregen has appointed Dr Klaas Zuideveld as chief executive officer [...]

    January 29, 2026
  • Biotech,CDMOs & Manufacturing,Clinical Development,Clinical Trials,Partnerships & Funding

    Evestia Clinical acquires ICRC-Weyer to expand full-service clinical research in Europe

    Evestia Clinical has acquired Berlin-based CRO and scientific consultancy ICRC-Weyer [...]

    January 29, 2026
  • Biotech,Clinical Trials,Funding,Regulatory Affairs

    MaaT Pharma reports H1 2025 results and advances Xervyteg regulatory pathway

    MaaT Pharma has reported its half year 2025 financial results, [...]

    January 26, 2026
Previous345Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Virica and Fujifilm target AAV manufacturing bottleneck with enhancer collaboration
    Categories: Biomanufacturing, Cell & Gene Therapy, Drug Development, Manufacturing, Partnerships & Funding
  • Allucent adds strategy leaders to expand therapeutic expertise
    Categories: Clinical Development, Drug Development, Healthcare leadership, Movers & Shakers, Neurosciences, Oncology, Rare Diseases
  • Circio raises NOK 250M in oversubscribed private placement to advance circRNA gene therapy platform
    Categories: Biotech, Funding, Genetic Diseases, Mergers & Acquisitions, Research & Development, RNA Therapeutics
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top